Insights into the management of emerging infections: Regulating variant creutzfeldt-jakob disease transfusion risk in the UK and the US

PLoS Medicine

Volumn 3, Issue 10, 2006, Pages 1751-1764

  Ponte, Maya L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B LYMPHOCYTE; BLOOD TRANSFUSION; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; DONOR SELECTION; EPIDEMIC; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE POLICY; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INTERVIEW; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PROPHYLAXIS; PUBLICATION; RISK MANAGEMENT; SOCIAL ASPECT; UNCERTAINTY; UNITED KINGDOM; UNITED STATES; REVIEW;

BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; GREAT BRITAIN; HUMANS; RISK MANAGEMENT; UNITED STATES;

EID: 33750862562     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030342     Document Type: Article

References (88)

1. Cinti S (2005) Pandemic influenza: Are we ready? Disaster Manag Response 3: 61-67.
2. Enserink M (2005) Influenza. Meeting seeks global consensus, highlights global disparities. Science 310: 1103.
3. Matthews L, Woolhouse M (2005) New approaches to quantifying the spread of infection. Nat Rev Microbiol 3: 529-536.
4. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 389: 498-501.
5. Butler D (1997) UK accused over risk of CJD in plasma...and latest BSE beef ban 'comes too late'. Nature 390: 541.
6. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, et al. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363: 417-421.
7. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364: 527-529.
8. Johnson RT (2005) Prion diseases. Lancet Neurol 4: 635-642.
9. Brown P, Bradley R (1998) 1755 and all that: A historical primer of transmissible spongiform encephalopathy. BMJ 317: 1688-1692.
10. Will RG (1993) Epidemiology of Creutzfeldt-Jakob disease. Br Med Bull 49: 960-970.
11. Collins S, McLean CA, Masters CL (2001) Gerstmann-Straussler-Scheinker syndrome,fatal familial insomnia, and kuru: A review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci 8: 387-397.
12. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial CJD: Classification and characterisation. Br Med Bull 66: 213-239.
13. Brown P, Preece M, Brandel JP, Sato T, McShane L, et al. (2000) Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55: 1075-1081.
14. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347: 921-925.
15. US Centers for Disease Control and Prevention (2005) Fact sheet: Variant Creutzfeldt-Jakob disease. Atlanta: US Centers for Disease Control and Prevention. Available: http://www.cdc.gov/ncidod/dvrd/vcjd/factsheet_nvcjd.htm Accessed 22 September 2006.
16. UK Department of Environment Food and Rural Affairs (2005) BSE: Statistics - BSE - GB weekly cumulative statistics. London: UK Department of Environment Food and Rural Affairs. Available: http://www.defra.gov.uk/animalh/ bse/statistics/weeklystats.html Accessed 22 September 2006.
17. Anderson RM, Donnelly CA, Ferguson NM, Woolhouse ME, Watt CJ, et al. (1996) Transmission dynamics and epidemiology of BSE in British cattle. Nature 382: 779-788.
18. Centers for Disease Control and Prevention (2004) Bovine spongiform encephalopathy in a dairy cow - Washington state, 2003. MMWR Morb Mortal Wkly Rep 52: 1280-1285.
19. TSE Advisory Committee (1998) Meeting. Bethesda: Department of Health and Human Services. Available: http://www.fda.gov/ohrms/dockets/ac/98/ transcpt/3484t1.pdf. Accessed 22 September 2006.
20. Pope C, Mays N (1995) Reaching the parts other methods cannot reach: An introduction to qualitative methods in health and health services research. BMJ 311: 42-45.
21. Hammersley M, Atkinson P (1995) Ethnography: Principles in practice. London, New York: Routledge. 323 p.
22. Strauss AL, Corbin JM (1998) Basics of qualitative research: Techniques and procedures for developing grounded theory. Thousand Oaks (California): Sage Publications. 312 p.
23. Strauss AL, Corbin JM (1990) Basics of qualitative research: Grounded theory procedures and techniques. Newbury Park (California): Sage Publications. 270 p.
24. Ruston A, Clayton J, Calnan M (1998) Patients' action during their cardiac event: Qualitative study exploring differences and modifiable factors. BMJ 316: 1060-1064.
25. Espin S, Levinson W, Regehr G, Baker GR, Lingard L (2006) Error or "act of God"? A study of patients' and operating room team members' perceptions of error definition, reporting, and disclosure. Surgery 139: 6-14.
26. Kuroda Y, Gibbs CJ Jr, Amyx HL, Gajdusek DC (1983) Creutzfeldt-Jakob disease in mice: Persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 41: 154-161.
27. Manuelidis EE, Gorgacs EJ, Manuelidis L (1978) Viremia in experimental Creutzfeldt-Jakob disease. Science 200: 1069-1071.
28. Diringer H (1984) Sustained viremia in experimental hamster scrapie. Brief report. Arch Virol 82: 105-109.
29. Rappaport EB (1987) Iatrogenic Creutzfeldt-Jakob disease. Neurology 37: 1520-1522.
30. Brown P (1988) Human growth hormone therapy and Creutzfeldt-Jakob disease: A drama in three acts. Pediatrics 81: 85-92.
31. Brown P (1995) Can Creutzfeldt-Jakob disease be transmitted by transfusion? Curr Opin Hematol 2: 472-477.
32. Menache D, O'Malley JP (1996) Creutzfeldt-Jakob disease: Current U.S. policy to further reduce the possible risk of transmission by transfusion. Biologicals 24: 277-283.
33. Kondo K, Kuroiwa Y (1982) A case control study of Creutzfeldt-Jakob disease: Association with physical injuries. Ann Neurol 11: 377-381.
34. Esmonde TF, Will RG, Slattery JM, Knight R, Harries-Jones R, et al. (1993) Creutzfeldt-Jakob disease and blood transfusion. Lancet 341: 205-207.
35. Davanipour Z, Alter M, Sobel E, Asher DM, Gajdusek DC (1985) A case-control study of Creutzfeldt-Jakob disease. Dietary risk factors. Am J Epidemiol 122: 443-451.
36. Evatt B, Austin H, Barnhart E, Schonberger L, Sharer L, et al. (1998) Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion 38: 817-820.
37. Hill AF, Zeidler M, Ironside J, Collinge J (1997) Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 349: 99-100.
38. Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, et al. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358: 171-180.
39. Cousens SN, Vynnycky E, Zeidler M, Will RG, Smith PG (1997) Predicting the CJD epidemic in humans. Nature 385: 197-198.
40. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM (1998) Estimation of the number of people incubating variant CJD. Lancet 351: 905-908.
41. Leveton LB, Sox HC, Stoto MAInstitute of Medicine (US) Committee to Study HIV Transmission Through Blood and Blood Products (1995) HIV and the blood supply: An analysis of crisis decisionmaking. Washington (D. C.): National Academy Press. 334 p.
42. Blood Safety and Availability Committee (1998) Meeting. Washington (D. C.): Department of Health and Human Services. Available: http://www.hhs. gov/bloodsafety/transcripts/jan30_98.html. Accessed 22 September 2006.
43. TSE Advisory Committee (1999) Meeting. Bethesda (Maryland): Department of Health and Human Services. Available: http://www.fda.gov/ohrms/ dockets/ac/99/transcpt/3518t1a.pdf. Accessed 22 September 2006.
44. TSE Advisory Committee (2000) Meeting. Gaithersburg (Maryland): Department of Health and Human Services. Available: http://www.fda.gov/ ohrms/dockets/ac/00/transcripts/3617t2a.pdf. Accessed 22 September 2006.
45. TSE Advisory Committee (1997) Meeting. Bethesda (Maryland): Department of Health and Human Services. Available: http://www.fda.gov/ohrms/ dockets/ac/97/transcpt/3345t2.pdf. Accessed 22 September 2006.
46. US Food and Drug Administration (2002) Guidance for industry: "Revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob (CJD) disease and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products". Available: http://www.fda.gov/cber/ gdlns/cjdvcjd.pdf Accessed 22 September 2006.
47. Ludlam CA (1998) New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation. Lancet 351: 1289-1290.
48. Reaney P, (27 February 1998) Britain to import blood plasma due to 'mad cow' risk. Reuters.
49. UK Department of Health (1998) Further precautionary measures on blood products announced. Press Release 98. London: UK Department of Health. Available: http://www.gnn.gov.uk/content/detail.asp?ReleaseID= 31884&NewsAreaID=2&NavigatedFromSearch=True. Accessed 22 September 2006.
50. Ellis R (4 November 1997) nvCJD donor blood products recalled. Press Association News.
51. European Agency for the Evaluation of Medicinal Products (1998) CPMP position statement on new variant CJD and plasma-derived medicinal products. London: European Agency for the Evaluation of Medicinal Products. Available: http://www.emea.eu.int/pdfs/human/press/pos/ 020198en.pdf. Accessed 22 September 2006.
52. UK Department of Health (2001) Summary of the meeting of the Committee on Safety of Medicines held on 11th February 1998. Medicines and Healthcare Products Regulatory Agency. London: UK Department of Health. Available: http://www.mhra.gov.uk/home/groups/l-cs-el/documents/ committeedocument/ con003343.pdf. Accessed 22 September 2006.
53. UK Department of Health (2001) Summary of the Committee on Safety of Medicines Meeting Held on 29th January 1998. Medicines and Healthcare Products Regulatory Agency. London: UK Department of Health. Available: http://www.mhra.gov.uk/home/groups/l-cs-el/documents/committeedocument/ con003344.pdf. Accessed 22 September 2006.
54. UK Department of Health (2001) Summary of the meeting of the Committee on Safety of Medicines held on Thursday 26th February 1998. Medicines and Healthcare Products Regulatory Agency. London: UK Department of Health. Available: http://www.mhra.gov.uk/home/groups/l-cs-el/documents/ committeedocument/con003342.pdf. Accessed 22 September 2006.
55. Spongiform Encephalopathy Advisory Committee (1997) Public summary of the meeting on 24th October 1997. London: Department for Environment, Food and Rural Affairs. Available: http://www.seac.gov.uk/summaries/summ_1097.htm. Accessed 22 September 2006.
56. Dzik WH (2002) Leukoreduction of blood components. Curr Opin Hematol 9: 521-526.
57. Klein MA, Frigg R, Flechsig E, Raeber AJ, Kalinke U, et al. (1997) A crucial role for B cells in neuroinvasive scrapie. Nature 390: 687-690.
58. Dobson F (1997) SEAC advice on safety of blood and blood products accepted. London: Department of Health. DoH 97/335 DoH 97/335.
59. UK Department of Health (1998) Government accepts advice on leucodepletion. Press Release 98. London: UK Department of Health. Available: http://www.gnn.gov.uk/content/detail.asp?ReleaseID=4583&NewsAreaID= 2&NavigatedFromSearch=True. Accessed 22 September 2006.
60. Lord Philips (chairman) (2000) The BSE Inquiry: The inquiry into BSE and variant CJD in the UK. London: Stationary Office: House of Commons.
61. Murphy MF (1998) Potential clinical benefits and cost savings of universal leucocyte-depletion of blood components. Transfus Sci 19: 343-346.
62. Comer P (1999) Assessment of the risk of exposure to vCJD infectivity in blood and blood products. London: Det Norske Veritas Limited Technical Consultancy Services.
63. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, et al. (1998) The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 38: 810-816.
64. Klein MA, Frigg R, Raeber AJ, Flechsig E, Hegyi I, et al. (1998) PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med 4: 1429-1433.
65. Brown KL, Stewart K, Ritchie DL, Mabbott NA, Williams A, et al. (1999) Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat Med 5: 1308-1312.
66. Pincock S (2004) Government confirms second case of vCJD transmitted by blood transfusion. BMJ 329: 251.
67. UK Department of Health (2004) Further precautions to protect the blood supply. Press Release. Available: http://www.gnn.gov.uk/content/detail. asp?ReleaseID=111656&NewsAreaID=2&NavigatedFromSearch=True. Accessed 22 September 2006.
68. King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, et al. (2004) Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 44: 25-29.
69. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL (2004) Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 44: 16-24.
70. Blumberg N, Fine L, Gettings KF, Heal JM (2005) Decreased sepsis related to indwelling venous access devices coincident with implementation of universal leukoreduction of blood transfusions. Transfusion 45: 1632-1639.
71. Hebert PC, Fergusson DA (2002) Evaluation of a universal leukoreduction program in Canada. Vox Sang 83 Suppl 1: 207-209.
72. Pietersz RN (2001) Universal leukoreduction in The Netherlands. Transfus Apher Sci 25: 209-210.
73. Gudmundsson S (2001) Universal leukoreduction in Iceland validation, process control and quality control. Implications for smaller bloodbanks. Transfus Apher Sci 25: 205-206.
74. Fisk JM, Snyder EL (2005) Universal pre-storage leukoreduction - A defensible use of hospital resources: the Yale-New Haven Hospital experience. Dev Biol (Basel) 120: 39-44.
75. Mitchell JC (1983) Case study and situational analysis. Sociological Review 27: 785-789.
76. Sharp K (1998) The case for case studies in nursing research: the problem of generalization. J Adv Nurs 27: 785-789.
77. Allio L, Ballantine B, Meads R (2005) Enhancing the role of science in the decision-making of the European Union. Regul Toxicol Pharmacol.
78. Anderson EL, Hilaire CS (2004) The contrast between risk assessment and rules of evidence in the context of international trade disputes: can the US experience inform the process? Risk Anal 24: 449-459.
79. Hergon E, Moutel G, Duchange N, Bellier L, Rouger P, et al. (2005) Risk management in transfusion after the HIV blood contamination crisis in France: the impact of the precautionary principle. Transfus Med Rev 19: 273-280.
80. Ramsey G (2004) Managing recalls and withdrawals of blood components. Transfus Med Rev 18: 36-45.
81. Resnik S (1999) Blood saga: hemophilia, AIDS, and the survival of a community. Berkeley: University of California Press. xvi, 292 p.
82. Choi BC (2005) Twelve essentials of science-based policy. Prev Chronic Dis 2: A16.
83. Latour B (1987) Science in action: how to follow scientists and engineers through society. Cambridge: Harvard University Press. 274 p.
84. Callon M (1986) The Sociology of an Actor-Network: The Case of the Electric Vehicle. In: Law J, editor. Mapping the dynamics of science and technology: sociology of science in the real world. Houndmills, Basingstoke, Hampshire: Macmillan. pp. xvii, 242.
85. Jasanoff S (1990) The fifth branch: science advisers as policymakers. Cambridge, Mass.: Harvard University Press. xiii, 302 p.
86. Ioannidis JP (2005) Why most published research findings are false. PLoS Med 2: e124.
87. Popay J, Rogers A, Williams G (1998) Rationale and standards for the systematic review of qualitative literature in health services research. Qual Health Res 8: 341-351.
88. Tobin GA, Begley CM (2004) Methodological rigour within a qualitative framework. J Adv Nurs 48: 388-396.